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Abstract: In this perspective, we congratulate the international efforts to highlight critical challenges
in brain tumor research through a recent Consensus Statement. We also illustrate the importance of
developing more accurate and clinically relevant early translational in vitro brain tumor models—a
perspective given limited emphasis in the Consensus Statement, despite in vitro models being widely
used to prioritize candidate therapeutic strategies prior to in vivo studies and subsequent clinical
trials. We argue that successful translation of effective novel treatments into the clinic will require
investment into the development of more predictive early pre-clinical models. It is in the interest of
researchers, clinicians, and ultimately, patients that the most promising therapeutic candidates are
identified and translated toward use in the clinic. Highlighting the value of early pre-clinical brain
tumor models and debating how such models can be improved is of the utmost importance to the
neuro-oncology research community and cancer research more broadly.
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1. Introduction
The recent Consensus Statement ‘Challenges to curing primary brain tumors [1]’, produced by a
Cancer Research UK convened panel of international experts, represents an important ‘call-to-arms’ to
the neuro-oncology research community and should be congratulated for highlighting areas worthy
of investment to improve patient outcomes. Agreement exists within the cancer research community
that more accurate genetically engineered mouse models (GEMMs) and orthotopic patient-derived
xenografts (PDXs), along with greater sharing of these resources, will help translate new treatments
into the clinic. However, it is important to consider that, in some contexts, these in vivo models may
only be as successful as the therapeutic strategies they are used to evaluate. Consequently, greater
emphasis should also be directed toward enhancing and validating early pre-clinical in vitro culture
systems used to model brain tumors.
2. The Value of Early Pre-Clinical Models in Brain Tumor Research
Using the example of targeting the DNA damage response (DDR) [2], effective future treatment
strategies may need to incorporate novel therapeutic combinations (such as combined PARP and
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ATR inhibition with Olaparib and AZD6738, respectively) to overcome the extensive intra-tumoral
heterogeneity brain tumors can exhibit, and functional redundancy governed by the interconnectedness
of many biological processes [3]. At least 19 novel drugs that target the DDR in cancer are currently
approved or in clinical trials [2]. Conservative estimates provide at least 147 potential two-drug or 939
three-drug DDR inhibitor combinations (excluding strategies that combine drugs of the same class).
In the quest to improve patient outcomes, all of these combinations may warrant evaluation, however,
testing every combination using rodent models would be impractical and potentially unethical.
Therefore, robust validation of biologically relevant in vitro models that are able to recapitulate
key disease features and predict clinical response may represent one of the most urgent and important
challenges facing our community.
3. A Need to Validate and Contrast In Vitro Models
Whilst organoids represent a promising 3D culture system highlighted in the Consensus Statement,
other clinically relevant 3D co-culture systems do exist [4,5], and the relative value of each to
prospectively determine which therapies extend survival for brain tumor patients in Phase III clinical
trials remains unclear. Furthermore, the Consensus Statement alludes to the blood–brain barrier (BBB)
representing a key obstacle to the efficient delivery of chemotherapy and novel therapeutics to brain
tumors [1]. In recent years, numerous advances in modeling the BBB have been made including
microfluidic ‘BBB on a chip’ systems [6] and multi-cellular BBB spheroids, based on non-adherent
co-culture of human astrocytes, pericytes, and brain endothelial cells [7]. Refining the ability of
in vitro models such as these to reproduce in vivo selectivity of both the BBB and blood-tumor barrier
remains critically important to accurately predict the ability of novel therapeutics to reach brain tumors.
Increasingly, the ‘gold-standard’ assessment of each should perhaps be based on the ability to predict
tumoral or peri-tumoral drug concentrations and intended target effects in Phase 0 clinical trials, rather
than animal studies. To prioritize novel therapies for the future, many researchers would benefit
from the clear validation of which in vitro BBB models best predict drug delivery in human subjects.
Greater investment in these areas is crucial to avoid the loss of talent within the research community
and ensure candidate therapies with the greatest likelihood of success are selected for in vivo studies
and subsequent clinical trials.
4. Toward Early Translational Models of Post-Surgical Disease
Additionally, worthy of consideration are the neurosurgical features of deriving human brain
tumor cells used in the majority of pre-clinical models, whether in vitro (2D, 3D, and organoid culture
systems) or in vivo (PDXs). Generally, these cells come from the resected tumor taken out at surgery,
even though the infiltrative residual cells left inside patients after surgery are responsible for disease
progression. For example, considering glioblastoma, which is characterized by extensive spatial and
temporal heterogeneity [8,9], it should not be assumed that the more invasive cells left behind after
surgery respond to treatment in an identical fashion to those cells that are removed. Consequently,
greater emphasis should be placed on the incorporation of typical residual cells into patient-derived
pre-clinical models. Our group and others are currently working on such models of clinically relevant
post-surgical residual disease, which we envisage will be valuable to the research community and help
prioritize the most promising novel therapies in the context of current multi-modal treatment.
5. Conclusions
Highlighting the value of early pre-clinical brain tumor models and debating how such models
can be improved is essential to enable the identification and translation of novel treatment strategies
that are most likely to be successful in clinical trials for patients with brain tumors. In cancer research,
developing more clinically relevant in vitro models to better prioritize novel therapies worthy of
further investigation is critical. The translational ‘pipeline’ may only ever be as successful as those
treatments which enter it.
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